MAY 20, 2016 6:38 AM PDT

Tumor Location Predicts Survival Odds in Colon Cancer

WRITTEN BY: Xuan Pham
Location, location, location! Researchers have found that colorectal patients whose tumor is located on the left side of the colon have better survival prognosis than patients whose tumor is located on the right side. The breaking discovery will be formally reported in June at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
 
Left vs. right really matters in colon cancer
In a large retrospective study of metastatic colorectal cancer, researchers identified data from 293 patients with right-sided primary tumors and 732 patients with left-sided primary tumors. The selected patients lacked mutations in the KRAS gene, which is known to influence response to certain drug therapies. The left side is defined as the descending colon, sigmoid colon, and rectum, whereas the right side includes the cecum and ascending colon.
 
Among the results, the key finding was that patients with left-sided primary tumors survived longer (33.3 months) than those with right-sided tumors (19.4 months). This trend persisted when the team factored in cetuximab and bevacizumab, two common therapies used to treat colorectal cancer. Cetuximab treatment prolonged survival to 36 months for left-sided tumors, while those with right-sided tumors lived 16.7 months. For bevacizumab, survival was 31.4 months for left-sided tumors, compared to 24.2 months for right-sided tumors.
 
Another interesting finding of the study is that drug effectiveness may be influenced by the location of the primary tumor. Right-sided tumors seem to respond better to bevacizumab than cetuximab, as reflected by longer patient survival (24.2 months and 16.7 months, respectively). By contrast, patients with left-sided tumors fared better with cetuximab than bevacizumab (36 months vs. 31.4 months). 
 
Cetuximab is a formidable defense against colorectal cancer, but recent studies have found that certain genetic mutations in KRAS influence whether this anticancer drug will be effective. In light of this, the team also conducted a separate analysis of 213 patients who carried KRAS mutations. Even in KRAS-mutated tumors, the team found that patients with left-sided tumor survived longer than patients with right-sided tumors.
 
“This is the largest study to date of tumor location in colorectal cancer, and it strongly suggests that this unexpected factor could answer some long-standing questions about why certain patients do better than others,” said ASCO President Julie Vose. “It is also an important reminder, in this exciting era of precision medicine, that genomics is not the only source of insight into how cancers should be studied and treated.”
 
Indeed, the primary location of the tumor in the colon appears to greatly influence the effectiveness of the treatment and overall patient survival. The biological mechanism driving this difference is currently being investigated.
 

Additional source: MNT, ASCO news release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 07, 2021
Cell & Molecular Biology
Overcoming Challenges to Detect Apoptosis in 3D Cell Structures
JUN 07, 2021
Overcoming Challenges to Detect Apoptosis in 3D Cell Structures
Researchers are increasingly relying on cells grown in three-dimensional (3D) structures to help answer their research q ...
JUN 08, 2021
Immunology
Fueling the Immune System's Killers
JUN 08, 2021
Fueling the Immune System's Killers
There’s a group of “killers” protecting your body against infections and eliminating potentially cance ...
JUL 08, 2021
Cancer
Activating p53 May Boost Efficacy of Cancer Immunotherapy
JUL 08, 2021
Activating p53 May Boost Efficacy of Cancer Immunotherapy
Pharmacological activation of the p53 protein in cancer cells leads to an anti-tumor immune response in lab tests. These ...
JUL 30, 2021
Cancer
Obesity Reduces Mortality in Advanced Prostate Cancer
JUL 30, 2021
Obesity Reduces Mortality in Advanced Prostate Cancer
Obese patients with an advanced form of prostate cancer survive longer than their slimmer counterparts, according to res ...
SEP 16, 2021
Technology
Scientists Create Tiny Replicas Of The Pancreas To Study New Drugs
SEP 16, 2021
Scientists Create Tiny Replicas Of The Pancreas To Study New Drugs
Pancreatic cancer it’s often hard to diagnose in its early stages, resulting in patients having more advanced canc ...
OCT 04, 2021
Cancer
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
OCT 04, 2021
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
Reports indicate that caffeine consumption in the United States is greatest in adults aged 50 – 64.  Coincide ...
Loading Comments...